Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Share This Author
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- A. Rittmeyer, F. Barlesi, D. Gandara
- MedicineThe Lancet
- 21 January 2017
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
- L. Gandhi, D. Rodríguez-Abreu, M. Garassino
- MedicineThe New England journal of medicine
- 16 April 2018
TLDR
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer
- S. Peters, D. Camidge, T. Mok
- Medicine, PsychologyThe New England journal of medicine
- 6 June 2017
TLDR
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
- J. Gainor, L. Dardaei, A. Shaw
- Biology, ChemistryCancer discovery
- 1 December 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
- C. Langer, S. Gadgeel, L. Gandhi
- MedicineThe Lancet. Oncology
- 1 November 2016
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the…
- S. Gadgeel, L. Gandhi, S. Ou
- MedicineThe Lancet. Oncology
- 1 September 2014
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- J. Gainor, L. Dardaei, A. Shaw
- Biology, Chemistry
- 1 October 2016
TLDR
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
- B. Solomon, B. Besse, A. Shaw
- MedicineThe Lancet. Oncology
- 1 December 2018
Rociletinib in EGFR-mutated non-small-cell lung cancer.
- L. Sequist, J. Soria, D. Camidge
- Medicine, BiologyThe New England journal of medicine
- 29 April 2015
TLDR
...
...